A rapid Candida albicans hyphal-form growth inhibition assay: determination of myelomonocytic-mediated antifungal activity

Mycoses ◽  
2009 ◽  
Vol 34 (3-4) ◽  
pp. 119-123 ◽  
Author(s):  
Lucia Scaringi ◽  
Elisabetta Blasi ◽  
Paola Cornacchione ◽  
Carla Bietta ◽  
F. Bistoni
Keyword(s):  
Candida Albicans ◽  
Antifungal Activity ◽  
Growth Inhibition ◽  
Inhibition Assay ◽  
Growth Inhibition Assay

scholarly journals Antifungal activity of components used for decontamination of dental prostheses on the growth of Candida albicans

2014 ◽  
Vol 43 (2) ◽  
pp. 137-142 ◽  
Author(s):  
Cíntia Lima Gouveia ◽  
Isabelle Cristine Melo Freire ◽  
Maria Luísa de Alencar e Silva Leite ◽  
Rebeca Dantas Alves Figueiredo ◽  
Leopoldina de Fátima Dantas de Almeida ◽  
...  
Keyword(s):  
Candida Albicans ◽  
Antifungal Activity ◽  
Sodium Bicarbonate ◽  
Fungal Growth ◽  
Antifungal Effect ◽  
Dental Prostheses ◽  
Diffusion Technique ◽  
Zones Of Inhibition ◽  
And Control

Introduction: The effectiveness of antimicrobial solutions employed in dental prosthesis decontamination is still uncertain. Aim: To evaluate the antifungal activity of cleaners used in the decontamination of dental prostheses on the growth of Candida albicans. Material and method: The evaluated products were: Corega Tabs(r) (S1), Sodium Hypochlorite 1% (S2), Sodium Bicarbonate 1% (S3), Hydrogen Peroxide 1% (S4), Chlorhexidine Digluconate 0.12% - Periogard (r) (S5), Mouthrinse based on essential oils - Listerine(r) (S6), essential oil from Rosmarinus officinalis (rosemary) at concentrations of 1% (S7) and 2% (S8). The antifungal activity of the products was evaluated by agar diffusion technique and the determination of microbial death curve of samples of C. albicans (ATCC 90028) in concentration 1.5 × 106 CFU/mL. The tests were performed in triplicate and statistical analysis was made by ANOVA Two-Way and Tukey tests, with the confidence level of 95%. Result: The average of the zones of inhibition growth, in millimeters, obtained for the products were: 0.0 (S1), 44.7 (S2), 0.0 (S3), 21.6 (S4), 10.0 (S5), 6.1 (S6), 0.0 (S7) and 2.4 (S8). Considering the determination of microbial death curve, all products showed a statistical difference (p<0.01) from control (0.85% sodium chloride) and S3 groups. Fungal growth less than 2×104 CFU/mL and an accentuation of the microbial death curve were observed after 30 minutes, with exception for S3 and control groups. Conclusion: The studied compounds, with the exception of Sodium Bicarbonate, have antifungal effect against C. albicans, which contribute for dental prostheses hygiene.

scholarly journals Sensitivity distribution of Venturia inaequalis to fenarimol in Québec apple orchards

2005 ◽  
Vol 75 (1) ◽  
pp. 35-43 ◽  
Author(s):  
O. Carisse ◽  
J.R. Pelletier
Keyword(s):  
Growth Inhibition ◽  
Frequency Distribution ◽  
Radial Growth ◽  
Venturia Inaequalis ◽  
Apple Scab ◽  
Inhibition Assay ◽  
Baseline Sensitivity ◽  
Growth Inhibition Assay ◽  
Sensitivity Distribution ◽  
Ergosterol Synthesis

This study was initiated to quantify the baseline sensitivity of apple scab (Venturia inaequalis) to fenarimol, an ergosterol synthesis-inhibiting fungicide. In 1988, 576 monoconidial isolates of Venturia inaequalis were collected from 26 commercial orchards throughout Quebec. Sensitivity to fenarimol was assessed by radial growth inhibition assay. The ED50 values for the 26 orchards ranged from 0.024 to 5.212 (μ g mL-1 with a mean ED50 of 0.156 μg ml-1. Reduced sensitivity, expressed as ED50, was found in three orchards for an overall frequency of 4.51% of isolates. Sensitive isolates had a mean ED50 of 0.079 μg ml-1, whereas isolates with reduced sensitivity had a mean ED50 of 1.714 μ g mL-1, yielding a resistance factor of about 22. Four populations were identified based on the frequency distribution of ED50 values.

scholarly journals Screening of Antifungal Azole Drugs and Agrochemicals with an Adapted alamarBlue-Based Assay Demonstrates Antibacterial Activity of Croconazole against Mycobacterium ulcerans

2012 ◽  
Vol 56 (12) ◽  
pp. 6410-6413 ◽  
Author(s):  
Nicole Scherr ◽  
Katharina Röltgen ◽  
Matthias Witschel ◽  
Gerd Pluschke
Keyword(s):  
Antibacterial Activity ◽  
Antifungal Activity ◽  
Standardized Test ◽  
Test Procedure ◽  
Mycobacterium Ulcerans ◽  
Inhibition Assay ◽  
Growth Inhibition Assay ◽  
Content Type ◽  
Compound Libraries ◽  
Slow Growing

ABSTRACTAn alamarBlue-based growth inhibition assay has been adapted for the thermosensitive and slow-growing pathogenMycobacterium ulcerans. The standardized test procedure enables medium-throughput screening of preselected compound libraries. Testing of a set of 48 azoles with known antifungal activity led to the identification of an imidazole antifungal displaying an inhibitory dose (ID) of 9 μM forM. ulcerans.

A new diatom growth inhibition assay using the XTT colorimetric method

2016 ◽  
Vol 185-186 ◽  
pp. 13-19 ◽  
Author(s):  
Weina Jiang ◽  
Takuya Akagi ◽  
Hidekazu Suzuki ◽  
Ayaka Takimoto ◽  
Hiroshi Nagai
Keyword(s):  
Growth Inhibition ◽  
Colorimetric Method ◽  
Inhibition Assay ◽  
Growth Inhibition Assay

scholarly journals Application of a whole blood mycobacterial growth inhibition assay to study immunity against Mycobacterium tuberculosis in a high tuberculosis burden population

PLoS ONE ◽  
2017 ◽  
Vol 12 (9) ◽  
pp. e0184563 ◽  
Author(s):  
Richard Baguma ◽  
Adam Penn-Nicholson ◽  
Erica Smit ◽  
Mzwandile Erasmus ◽  
Jonathan Day ◽  
...  
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Growth Inhibition ◽  
Whole Blood ◽  
Inhibition Assay ◽  
Growth Inhibition Assay ◽  
Mycobacterial Growth

scholarly journals Evaluation of Tuberculosis Vaccine Candidate, pcDNA3.1-rpfD using Mycobacterial Growth Inhibition Assay (MGIA)

2021 ◽  
Vol 29 (1) ◽  
pp. 1-8
Author(s):  
Mifa Nurfadilah ◽  
Andriansjah Rukmana ◽  
Fithriyah Sjatha
Keyword(s):  
Growth Inhibition ◽  
Vaccine Candidate ◽  
Negative Control ◽  
Automated System ◽  
Control Group ◽  
Functional Assay ◽  
Inhibition Assay ◽  
Peripheral Blood Mononuclear ◽  
Growth Inhibition Assay ◽  
Mycobacterial Growth

Resuscitation-promoting factor D (RpfD) is a protein involved in the resuscitation of dormant bacteria. A new tuberculosis vaccine carrying the rpfD gene has been successfully constructed, pcDNA3.1-rpfD. It was demonstrated that this vaccine exhibits cellular and humoral immune responses. Therefore, within this study, the efficacy of this new vaccine candidate was evaluated using mycobacterial growth inhibition assay (MGIA). MGIA is a functional assay that measures the complex host immune response, peripheral blood mononuclear cell (PBMC) and splenocyte from BALB/c mice against mycobacteria. With BACTECTM MGITTM 960 automated system, the effect of vaccination on bacterial growth was reported as a time to positivity (TTP) in hours. The mean of TTP from the vaccinated group (both pcDNA3.1-rpfD and BCG) was higher than the negative control group. These results suggest that pcDNA3.1-rpfD may be effective in controlling tuberculosis growth and may provide a clue for the development of the tuberculosis vaccine. In addition, despite previous evidence that IFNγ was essential for tuberculosis immunity, IFNγ (interferon gamma) production was found not to be correlated with mycobacterial inhibition. Therefore, these findings offer an alternative method to evaluate vaccine candidates than the assessment using IFNγ only.

scholarly journals Ex vivo mycobacterial growth inhibition assay (MGIA) for tuberculosis vaccine testing - a protocol for mouse splenocytes

2015 ◽  
Author(s):  
Andrea Andrea Zelmer ◽  
Rachel Tanner ◽  
Elena Stylianou ◽  
Sheldon Morris ◽  
Angelo Izzo ◽  
...  
Keyword(s):  
Immune Response ◽  
Clinical Trials ◽  
Growth Inhibition ◽  
Ex Vivo ◽  
Inhibition Assay ◽  
Growth Inhibition Assay ◽  
Mouse Splenocytes ◽  
Vaccine Testing ◽  
Mycobacterial Growth ◽  
Detailed Protocol

The testing of vaccines for tuberculosis is costly and time-consuming, and dependent on preclinical animal challenge models and clinical trials. We have recently developed a mycobacterial growth inhibition assay (MGIA) to test vaccine efficacy ex vivo. This assay measures the summative effect of the host immune response and may serve as a novel tool to facilitate vaccine testing. It has generated much interest recently, and to facilitate technology transfer and reproducibility between laboratories, we here describe a detailed protocol for an ex vivo MGIA in mouse splenocytes.

Sign in / Sign up

Export Citation Format

Share Document